Commitments and Contingencies	9 Months Ended
Sep. 30, 2021
Commitments and Contingencies
Commitments and Contingencies	9. Commitments and Contingencies Drug Supplier Project Plan –Total commitments for the Company’s drug supplier project plan were $3.0 million as of September 30, 2021, comprised of $1.9 million for the manufacture of prexigebersen, BP1002, and BP1003 drug products, $0.9 million for manufacture of the Company’s Grb2 drug substance, $0.1 million for manufacturing development and $0.1 million for testing services. The Company expects to incur $2.2 million of these commitments over the next 12 months.

The entire disclosure for commitments and contingencies.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Name:	us-gaap_CommitmentsAndContingenciesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration